Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom
about
Herpes zoster in Germany: quantifying the burden of diseaseHerpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspectiveHerpes Zoster and Postherpetic Neuralgia: Practical Consideration for Prevention and TreatmentSimilar herpes zoster incidence across Europe: results from a systematic literature reviewCost of shingles: population based burden of disease analysis of herpes zoster and postherpetic neuralgiaQuantification of risk factors for herpes zoster: population based case-control studyNeuropathic itchAdvances in the understanding of the pathogenesis and epidemiology of herpes zosterEpidemiology of herpes zoster infection among patients treated in primary care centres in the Valencian community (Spain).The impact of herpes zoster and post-herpetic neuralgia on quality-of-life.Burden of herpes zoster and postherpetic neuralgia in Japanese adults 60 years of age or older: Results from an observational, prospective, physician practice-based cohort study.Predictors of pain intensity and persistence in a prospective Italian cohort of patients with herpes zoster: relevance of smoking, trauma and antiviral therapyPostherpetic Neuralgia Presenting as Delusional Parasitosis: A Case SeriesBurden of post-herpetic neuralgia in a sample of UK residents aged 50 years or older: findings from the Zoster Quality of Life (ZQOL) studySystematic review of incidence and complications of herpes zoster: towards a global perspective.A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK.Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study.Prevalence and healthcare utilization of herpes zoster and postherpetic neuralgia in South Korea: disparity among patients with different immune statuses.Herpes zoster incidence among insured persons in the United States, 1993-2006: evaluation of impact of varicella vaccination.Epidemiological characteristics and societal burden of varicella zoster virus in the Netherlands.Cost-effectiveness of vaccination against herpes zoster.Herpes zoster: diagnostic, therapeutic, and preventive approaches.Challenges in quantifying the patient-reported burden of herpes zoster and post-herpetic neuralgia in the UK: learnings from the Zoster Quality of Life (ZQOL) study.Burden of herpes zoster in the UK: findings from the zoster quality of life (ZQOL) study.One-year follow-up of patients with long-lasting post-herpetic neuralgia.Population-based study of the epidemiology of herpes zoster in Korea.ARIZONA study: is the risk of post-herpetic neuralgia and its burden increased in the most elderly patients?Burden of herpes zoster-associated chronic pain in Italian patients aged 50 years and over (2009-2010): a GP-based prospective cohort studyIncidence of herpes zoster and persistent post-zoster pain in adults with or without diabetes in the United StatesHealth economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.Varicella vaccination alters the chronological trends of herpes zoster and varicella.The humanistic, economic and societal burden of herpes zoster in Europe: a critical reviewEvaluation of the economic burden of Herpes Zoster (HZ) infection.Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland.A pathway to leadership for adult immunization: recommendations of the National Vaccine Advisory Committee: approved by the National Vaccine Advisory Committee on June 14, 2011Epidemiology and cost of herpes zoster and postherpetic neuralgia among patients treated in primary care centres in the Valencian community of Spain.Burden of herpes zoster and post-herpetic neuralgia in Sweden.Immunogenicity and safety of ZOSTAVAX(®) approaching expiry potency in individuals aged ≥50 years.Burden of herpes zoster: the direct and comorbidity costs of herpes zoster events in hospitalized patients over 50 years in France.5% Lidocaine Medicated Plaster for the Treatment of Postherpetic Neuralgia: A Review of the Clinical Safety and Tolerability.
P2860
Q21261833-47AC8066-ECFA-4B96-ACB3-B56661197B68Q26781940-F1D84FE4-2F02-4ACD-9CE6-7B460B18867AQ26801569-DE63E66F-B312-4801-B06E-9ADBE8D0AA7BQ26824836-032FC5D5-1F29-4F27-9CD3-C3913D18B39EQ28468596-06971022-F572-48D6-B128-A19CB085CE03Q28657403-F032BA92-6BD2-4930-8108-045693DCFCF6Q30467238-7319F440-0906-40D9-8CB8-78EDA713EA23Q33562824-2A3D0F33-2C41-45B2-9A1A-7F8FD113135CQ33574978-0B27BAD7-A793-44CE-83DF-9532729CE49FQ33611436-ADF82221-D087-41F4-8C33-3D830D5B1E6EQ33626007-42AE35A9-81E2-40FA-BFF3-E4AB851DB443Q33714978-2980B1DD-4C8D-49A6-A2B8-DFC24D1EE1E2Q33772056-1B3BFD19-D735-467E-BB7E-1E382EB0E213Q33776676-EFA05A3B-B871-4E94-9583-6EE97991DFCCQ33795551-0E5C948D-70BB-47C7-A16F-976472AC1694Q33894866-92AC1430-FEC6-4E01-88F5-77AD2F124066Q34064838-C593537B-5F12-4B33-8773-02CA5C0C7FF4Q34125709-F2A46A41-D5ED-4273-9273-6C38B45335A5Q34158156-3FBE9667-9353-49B8-8724-CC22BFCE5814Q34265188-8E5F9B9D-869C-454B-B3ED-A133144847E8Q34291150-2AB0BDCE-1C93-49D8-B931-2A1F210741A2Q34376752-57AF3566-F79F-4ABE-BE1B-6524782D5949Q34461800-18437243-4653-48DE-BE8D-53474ADCA47AQ34468957-4C92F45C-C5E8-4D51-993B-6DFC313FA5A6Q34484576-6E3721DB-746E-4C47-A961-12F107FAF4E0Q34592021-8DCFB7FB-2A17-4746-8815-09923D9C66CFQ34667569-914C9AC7-9D81-4F3D-ACE5-2CE9D4AF7032Q34721426-EB40CBD9-A4A9-45F2-BF1F-D4B1B0A697BBQ34801907-1EA4AADF-8449-4C0D-9E58-D5F05B67C738Q35000186-FAF5014C-3B42-4D6D-A7D2-E1BEEA5EC24DQ35035512-A7AEDC79-9436-4817-AD6D-038829F3ABDBQ35147612-CFE38E7F-79A0-4751-81A1-FC8FEA4C9572Q35498396-B959E95E-52A9-4F8E-8E14-24E21260715DQ35558544-AB9E2A2F-752F-4C7D-B6E2-4B2D6D10CD20Q35606837-40E3F752-DD06-4BCF-9348-9E23A5604C1FQ35607755-C5A4B054-5D59-407E-9762-C11F3F53F64EQ35639805-FFF7471D-7FF3-4506-AED6-A3BD924C0B0DQ35667362-B8B13FA8-85C9-4926-A086-5961A6DDE9F5Q35749707-CE2B7092-B1C9-47DC-A7D1-0DB052CFB3E4Q35752545-58381D23-03F1-4A57-8EB8-57AAE434BE45
P2860
Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom
description
im Mai 2008 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 09 May 2008
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в травні 2008
@uk
name
Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom
@en
Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom
@nl
type
label
Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom
@en
Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom
@nl
prefLabel
Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom
@en
Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom
@nl
P2093
P2860
P1476
Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom
@en
P2093
P2860
P356
10.1017/S0950268808000678
P577
2008-05-09T00:00:00Z